Sunday, 18 February 2018

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Thursday, the companies revealed Bavencio (avelumab) had failed to outdo chemo at extending the lives of second-line lung cancer patients with PD-L1-positive tumors. And the way Evercore ISI analyst Umer Raffat sees it, there’s no “good reason” to explain the flop.

No comments:

Post a Comment

5 steps to use cold press to bring down fever in a child

Use cold press to bring down fever in a child 1. What you will do is to put some cool tap water in a bowl. If you like you can add a few...